Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eculizumab treatment alters the proteometabolome beyond the inhibition of complement.
Nelke C, Schroeter CB, Stascheit F, Huntemann N, Pawlitzki M, Willison A, Räuber S, Melzer N, Distler U, Tenzer S, Stühler K, Roos A, Meisel A, Meuth SG, Ruck T. Nelke C, et al. Among authors: willison a. JCI Insight. 2023 Jul 10;8(13):e169135. doi: 10.1172/jci.insight.169135. JCI Insight. 2023. PMID: 37227781 Free PMC article.
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
Ruck T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C, Schroeter CB, Willison A, Heming M, Müntefering T, Melzer N, Krämer J, Lindner M, Riepenhausen M, Gross CC, Klotz L, Bittner S, Muraro PA, Schneider-Hohendorf T, Schwab N, Meyer Zu Hörste G, Goebels N, Meuth SG, Wiendl H. Ruck T, et al. Among authors: willison a. Brain. 2022 Jun 3;145(5):1711-1725. doi: 10.1093/brain/awac064. Brain. 2022. PMID: 35661859 Free PMC article.
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S, Willison A, Korsen M, Kölsche T, Golombeck KS, Plaack B, Schüller J, Huntemann N, Rolfes L, Schroeter CB, Nelke C, Regner-Nelke L, Förster M, Ringelstein M, Barnett MH, Hartung HP, Aktas O, Albrecht P, Ruck T, Melzer N, Meuth SG, Kremer D. Räuber S, et al. Among authors: willison a. Front Immunol. 2022 Dec 23;13:1037214. doi: 10.3389/fimmu.2022.1037214. eCollection 2022. Front Immunol. 2022. PMID: 36618356 Free PMC article.
Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies.
Masanneck L, Rolfes L, Regner-Nelke L, Willison A, Räuber S, Steffen F, Bittner S, Zipp F, Albrecht P, Ruck T, Hartung HP, Meuth SG, Pawlitzki M. Masanneck L, et al. Among authors: willison a. Mult Scler Relat Disord. 2022 Jul;63:103927. doi: 10.1016/j.msard.2022.103927. Epub 2022 May 28. Mult Scler Relat Disord. 2022. PMID: 35700670 Free article.
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.
Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, Kölsche T, Korsen M, Grothe M, Groppa S, Luessi F, Engel S, Nelles G, Bonmann E, Roick H, Friedrich A, Knorn P, Landefeld H, Biro Z, Ernst M, Bayas A, Menacher M, Akgün K, Kleinschnitz C, Ruck T, Ziemssen T, Pul R, Meuth SG. Regner-Nelke L, et al. Among authors: willison a. Neurol Res Pract. 2022 Nov 7;4(1):55. doi: 10.1186/s42466-022-00219-3. Neurol Res Pract. 2022. PMID: 36336685 Free PMC article.
Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019.
Pawlitzki M, Acar L, Masanneck L, Willison A, Regner-Nelke L, Nelke C, L'hoest H, Marschall U, Schmidt J, Meuth SG, Ruck T. Pawlitzki M, et al. Among authors: willison a. Neurol Res Pract. 2022 Dec 29;4(1):62. doi: 10.1186/s42466-022-00226-4. Neurol Res Pract. 2022. PMID: 36581896 Free PMC article.
27 results